The FDA approved Eli Lilly’s Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.
Eli Lilly’s Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
